Introduction {#section5-1178633719882929}
============

Enterococci, which were initially considered to be harmless flora of the gastrointestinal tract, have emerged in the last two decades as a major cause of hospital-acquired infections (HAIs),^[@bibr1-1178633719882929]^ including surgical site infections, urinary tract infections, and bacteremia.^[@bibr1-1178633719882929][@bibr2-1178633719882929]-[@bibr3-1178633719882929]^ In the past, the source of infection by enterococci was mainly endogenous^[@bibr4-1178633719882929]^; after that, the transmission of enterococci among hospitalized patients was reported.^[@bibr5-1178633719882929]^ *Enterococcus faecalis* is one of the most common isolated pathogens from all types of wounds,^[@bibr6-1178633719882929],[@bibr7-1178633719882929]^ and the third frequent isolated pathogen from surgical site infections.^[@bibr8-1178633719882929],[@bibr9-1178633719882929]^ They are also account to be an important cause of bacteremia all over the world.^[@bibr10-1178633719882929]^ Colonization of the hands of health care workers by *E faecalis* can be a source of infection by contact with surfaces, or medical equipment^[@bibr11-1178633719882929]^ due to its ability to survive on inanimate surfaces, as well as on the hands of hospital staff for long time.^[@bibr12-1178633719882929]^ Treatment of *E faecalis* infections is so difficult because they have intrinsic and acquired resistance to many antimicrobials.^[@bibr13-1178633719882929]^ They have intrinsic resistance against a number of antimicrobials including, aminoglycosides and β-lactams due to carrying several resistance genes^[@bibr14-1178633719882929]^ as well as acquired resistance against several antibiotics like macrolides, vancomycin, cephalosporin, tetracycline, and fluoroquinolones, resulting from either DNA mutation or acquisition of new genes through gene transfer.^[@bibr15-1178633719882929]^ Most hospital strains are resistant to a wide range of antibiotics, including macrolide and vancomycin,^[@bibr15-1178633719882929][@bibr16-1178633719882929]-[@bibr17-1178633719882929]^ and also have been recognized as β-lactamases producers, causing resistance to penicillins and cephalosporins.^[@bibr18-1178633719882929]^ Few studies have focused on *E faecalis* isolated from surgical wound infections and bacteremia. In this regard, little is known about the prevalence of *E faecalis* isolated from surgical wound infections and bacteremia, their antimicrobial susceptibility, and the mechanisms of antibiotic resistance particularly in developing countries, which are investigated in the current study

Patients and Methods {#section6-1178633719882929}
====================

Patient population {#section7-1178633719882929}
------------------

This is a cross-sectional study including 300 patients who developed clinical signs of surgical wound infection and bacteremia at least 48 hours after hospital admission as identified by the Centers for Disease Control and Prevention National Healthcare Safety Network (CDC/NHSN),^[@bibr19-1178633719882929]^ from surgery departments at Minia University hospital (a teaching hospital provides care to adult and pediatric patients in 35 wards including 800 beds), between June 2017 and January 2018. Samples were collected as the following: 200 wound swaps from patients with clinical signs of septic wounds and 100 blood cultures from patients with suggested bacteremia. The study protocol was approved by the local institutional review board at the authors' affiliated institution (Registration number: MUH15329) and consents were obtained from all participants.

Bacterial isolation {#section8-1178633719882929}
-------------------

Identification of the isolated *enterococci* to the genus level was performed by Gram staining, blackening of Bile Aesculin Azide Agar (Oxoid), culture on nutrient broth at 10°C, 45°C, and with 6.5% NaCl, then identification to the species level was performed by motility test, sugar fermentation tests (L-Arabinose, Mannitol, Sorbitol Glycerol D-Lyxose Mannitol, Galactose, and Hippurate), and arginine dihydrolase and pyruvate utilization test. Also identification of *E faecalis* strains confirmed by detection of *E Faecalis* gene using real-time polymerase chain reaction (PCR).

Antimicrobial susceptibility testing {#section9-1178633719882929}
------------------------------------

Antimicrobial susceptibility of the isolates was determined by disk diffusion method for the following antibacterial agents; erythromycin (15 µg), gentamicin (120 μg), tetracycline (30 μg), ampicillin (10 µg), amoxicillin-clavulanic (30 µg), Cefepime (30 µg), vancomycin (30 μg), teicoplanin (30 μg), linezolid (30 μg), ciprofloxacin (5 μg), Imipenem (10 µg), and rifampin (5 μg) (Bioanalyse, Turkey). Muller-Hinton agar plates were inoculated with 0.5 McFarland standard suspension of the strains, antimicrobial disks were placed into plates and then were incubated at 37°C for 24 hours. Minimum inhibitory concentrations (MICs) of vancomycin and erythromycin were determined by the agar dilution method. Zone diameters were assessed according to the Clinical Laboratory Standard Institute guidelines.^[@bibr20-1178633719882929]^

DNA extraction {#section10-1178633719882929}
--------------

DNA was extracted using genomic BYF DNA extraction Mini Kit (Intron Biotechnology, Korea) according to the manufacturer's instructions.

Identification of *E faecalis* Gene and Resistance Genes Using Real-Time PCR {#section11-1178633719882929}
============================================================================

The *ddl E faecalis* gene, *ere(B)* gene for erythromycin resistance, *van A* gene for vancomycin resistance, *blaSHV* and *blaTEM* genes for extended spectrum beta-lactamase (ESBL) production were amplified by PCR in all isolates. The primer sets used (Eurofins, Germany) for amplification of *ddl E faecalis*,^[@bibr21-1178633719882929],[@bibr22-1178633719882929]^ *van A*,^[@bibr21-1178633719882929]^ *ere(B)*,^[@bibr23-1178633719882929]^ *blaSHV*,^[@bibr24-1178633719882929]^ and *blaTEM*^[@bibr25-1178633719882929]^ genes are shown in [Table 1](#table1-1178633719882929){ref-type="table"}. PCR was performed in 20 µL; 10 µL Hot Start Maxima SYBR green qPCR Master Mix (2X), 10 pmoles/µL forward primer and 10 pmoles/µL reverse primer (Macrogen, Korea), 0.05µL ROX solution, 200 ng of DNA and completed to 20 µL with nuclease-free water. PCR reactions were performed using real-time thermal cycler (Applied Biosystem 7500 fast), with a fluorescence detector. Each sample was tested in duplicate in the same Reverse Transcriptase PCR experiment. Standard curves and other data analysis were analyzed with Applied Biosystem Real-time Software.

###### 

Primers sequences used for PCR assays.

![](10.1177_1178633719882929-table1)

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Genes          Primer sequence                                                                  Reference
  -------------- -------------------------------------------------------------------------------- -------------------------------------------------
  *ddl*\         F: ATCAAGTACAGTTAGTCT\                                                           Duka et al^[@bibr21-1178633719882929]^\
  *E Faecalis*   R: ACGATTCAAAGCTAACTG                                                            Drahovska et al^[@bibr22-1178633719882929]^

  *van A*        F: GGGAAAACGACAATTGC\                                                            Duka et al^[@bibr21-1178633719882929]^
                 R: GTACAATGCGGCCGTTA                                                             

  *ere(B)*       F: 59-AGA AAT GGA GGT TCA TAC TTA CCA-39 R: 59-CAT ATA ATC ATC ACC AAT GGCA-39   Portillo et al^[@bibr23-1178633719882929]^

  *blaSHV*       ATTTGTCGCTTCTTTACTCGC\                                                           Jemima and Verghese^[@bibr24-1178633719882929]^
                 TTTATGGCGTTACCTTTGAC                                                             

  *blaTEM*       ATGAGTATTCAACATTTCCG\                                                            Tofteland et al^[@bibr25-1178633719882929]^
                 CCAATGCTTAATCAGTGAGG                                                             

  *erm(B)*       F: GAAAAGGTACTCAACCAAATA\                                                        Sutcliffe et al^[@bibr26-1178633719882929]^
                 R: GTAACGGTACTTAAATTGTTTAC                                                       

  *mef(A/E)*     F: AGTATCATTAATCACTAGTGC\                                                        Sutcliffe et al^[@bibr26-1178633719882929]^
                 R: AGTATCATTAATCACTAGTGC                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------

Detection of erythromycin resistance genes, erm(B), and mef(A/E) by conventional PCR {#section12-1178633719882929}
------------------------------------------------------------------------------------

PCR reactions were performed using thermal cycler (UNO II thermocycler, Biometra, Germany), 50 µL reaction: 25 µL DreamTaq Green PCR Master Mix (2X), 20 pmoles/µL for forward and reverse primer, 300 ng of DNA and completed to 50 µL with nuclease-free deionized water. Each gene was amplified using its specific primer^[@bibr26-1178633719882929]^ ([Table 1](#table1-1178633719882929){ref-type="table"}) (Eurofins Genomic Co., Germany). Positive and negative controls from previous research were used.^[@bibr27-1178633719882929]^ PCR products were resolved on 2% agarose gel and visualized under a UV transilluminator (Biometra).

Statistical analysis {#section13-1178633719882929}
--------------------

Categorical variables were analyzed using the chi-square test, using SPSS software (version 20). *P* values of \< .05 were considered to be statistically significant.

Results {#section14-1178633719882929}
=======

Characteristics of the study population {#section15-1178633719882929}
---------------------------------------

Out of 300 bacterial isolates, 26 (8.6%) *E faecalis* isolates were identified. Only one isolate per patient was detected. The majority of them (24/26) were isolated from patients with surgical wound infections. *E faecalis* was recovered with a frequency of 24/200 (12%), from surgical wound samples and 2/100 (2%) from blood cultures as shown in [Table 2](#table2-1178633719882929){ref-type="table"}.

###### 

Characterization of *E Faecalis* isolated from hospital-acquired surgical wound infection and bacteremia.

![](10.1177_1178633719882929-table2)

  Isolate No.   Location of patient   Specimen   Erythromycin-resistant genes   Bla genes   Vancomycin-resistance genes   Antibiotic-resistance pattern        
  ------------- --------------------- ---------- ------------------------------ ----------- ----------------------------- ------------------------------- ---- ------------------------------------------------
  1             Surgical ward         Wound      \+                             \_          \+                                                                 TE, AM, FEP, E, RD, **CN**, AMC, CIP, LNZ
  2             Surgical ward         Wound      \_                             \_          \+                            --                                   TE, AM, FEP E, RD, CN
  3             Surgical ward         Wound      \+                             \_          \+                            --                              \+   TE, AM, FEP, E, RD, CN, CIP, AMC, Va
  4             Surgical ward         Wound      \+                             \_          \+                            --                              \+   TE, AM, FEP, E, RD, CN CIP AMC Va
  5             Surgical ward         Wound      \+                             \_          \+                            --                              \+   TE, AM, FEP, E, RD, CN, AMC, CIP, Va, LNZ
  6             Surgical ward         Wound      \_                             \_          \+                            --                                   TE, AM, FEP, E, RD, CN
  7             Surgical ward         Wound      \+                             \_          \+                            --                              \+   TE, AM, FEP, E, RD, CN, AMC, CIP, Va, LNZ
  8             Surgical ward         Wound      \_                             \_          \+                            --                                   TE, AM, FEP, E, RD, CN, Va
  9             Surgical ward         Wound      \+                             \_          \+                            --                              \+   TE, AM, FEP, E, RD, CN, AMC, CIP, Va, IPM, LNZ
  10            Surgical ward         Wound      \+                             \_          \+                            --                              \+   TE, AM, FEP, E, RD, CN, AMC, CIP, Va
  11            Surgical ward         Wound      \+                             \_          \+                            --                              \+   TE, AM, FEP, E, RD, CN, AMC, CIP, Va
  12            Surgical ward         Wound      \_                             \_          \_                            --                                   TE, AM, FEP, E
  13            Surgical ward         Wound      \+                             \_          \+                            --                              \+   TE, AM, FEP, E, RD, CN AMC, CIP, Va, LNZ
  14            Surgical ward         Wound      \+                             \_          \+                            --                              --   TE, AM, FEP, E, RD, CN, AMC, CIP, Va
  15            Surgical ward         Wound      \+                             \_          \+                            --                                   TE, AM, FEP, E, RD, CN, AMC, CIP
  16            Surgical ward         Wound      \_                             \_          \_                            --                                   TE, AM, FEP, E, RD,
  17            Surgical ward         Wound      \_                             \_          \+                            --                                   TE, AM, FEP, E, RD, CN, AMC
  18            Surgical ward         Wound      \+                             \_          \+                            --                                   TE, AM, FEP, E, RD, CN, CIP
  19            Surgical ward         Wound      \+                             \_          \_                            --                                   TE, AM, FEP, E, RD, CN, AMC
  20            Surgical ward         Wound      \+                             \_          \+                            --                                   TE, AM, FEP, E, RD, CN, AMC
  21            Surgical ward         Wound      \+                             \_          \+                            --                              \+   TE, AM, FEP, E, RD, CN, AMC, CIP, Va, LNZ
  22            Surgical ward         Wound      \_                             \_          \+                            --                              --   TE, AM, FEP, E, RD, CN, AMC, Va
  23            Surgical ward         Wound      \+                             \_          \+                            --                              \+   TE, AM, FEP, E, RD, CN, AMC, CIP, Va, IPM
  24            Surgical ward         Wound      \+                             \_          \_                            --                              --   TE, AM, FEP, E, AMC, CIP, Va
  25            Surgical ward         Blood      \_                             \_          \_                            --                                   TE, AM, FEP, E
  26            Surgical ward         Blood      \_                             \_          \_                            --                                   TE, AM, FEP

Abbreviations: AM, ampicillin; AMC, amoxicillin-clavulanic; CIP, ciprofloxacin; CN, gentamicin; E, erythromycin; FEP, cefepime; IPM, imipenem; LNZ, linezolid; RD, rifampin; TE, teicoplanin; TE3, tetracycline; Va, vancomycin.

Antimicrobial susceptibility {#section16-1178633719882929}
----------------------------

Among the 26 tested *E faecalis* isolates, 100% were resistant to cefepime, ampicillin, and tetracycline, 25 (96%) to erythromycin, 22/26 (84.6%) to rifampin, 21 (80%) to gentamicin (120 μg), 18 (69.2.8%) to amoxicillin-clavulanic, 15 (61.5%) to ciprofloxacin, 14 (53.8%) to vancomycin, 6 (23.1%) to linezolid, 5 (19.2%) to teicoplanin, and 2 (7.6%) to imipenem. For vancomycin, MIC of all vancomycin-resistant isolates were ⩾ 128 μg/mL. Multidrug resistance (MDR) was detected in all isolates (100%) as shown in [Figure 1](#fig1-1178633719882929){ref-type="fig"} and [Table 2](#table2-1178633719882929){ref-type="table"}.

![Antimicrobial resistance patterns of *E facalis* isolated from hospital-acquired infections.\
Amox-clav indicates amoxacillin-clavulanic acid; cipro, ciprofloxacin, vancom, vancomycin.](10.1177_1178633719882929-fig1){#fig1-1178633719882929}

Detection of resistance genes {#section17-1178633719882929}
-----------------------------

Out of 25 erythromycin-resistant isolates, 20 (80%) were found to be positive for *ere(B)* gene, 17 (68%) were found to be positive for *erm(B)* gene ([Figure 2](#fig2-1178633719882929){ref-type="fig"}), all (26) *E faecalis* isolates were negative for *mef(A/E)* gene. Fifteen isolates carry both *ere B* and *erm(B)* genes, while 2 isolates carry *erm(B)* gene only and 5 isolates carry *ere(B)* gene only. *Van A* was detected in 10/14 (71.4%) of vancomycin-resistant isolates. Genes encoding--lactamases (*blaTEM* and *blaSHV*) were not detected in any of isolates ([Table 2](#table2-1178633719882929){ref-type="table"}).

![Gel electrophoresis for PCR products detecting erm B gene; lane 1: 100 bp molecular weight marker, lane 2: positive control, lane 3: negative control, lane 4, 6, and lanes 9-12: positive strains (639 bp), lanes 5, 7, and 8: negative strains.](10.1177_1178633719882929-fig2){#fig2-1178633719882929}

Discussion {#section18-1178633719882929}
==========

Enterococci are frequently isolated from health care settings. They reported as the third most common hospital-acquired pathogen.^[@bibr28-1178633719882929]^ They are increasingly isolated from traumatic and surgical wounds^[@bibr29-1178633719882929]^ and from bacteremia.^[@bibr10-1178633719882929]^ In the present study, the prevalence of E. faecalis isolation was 8.6% among 300 Egyptian patients with hospital-acquired infections. The isolation rate was higher in surgical wound samples; 24/200 (12%) than blood samples (2%). Our findings were higher than other reports, where *E faecalis* was isolated from wound swabs with percentages of 6%^[@bibr30-1178633719882929]^ and 1.3%,^[@bibr31-1178633719882929]^ and were lower than others where the isolation rate from blood cultures was (4.6%).^[@bibr32-1178633719882929]^ Our study showed that all isolates were reported to be resistant to cefepime, ampicillin, tetracycline, and exhibited high resistance rates; (84.6%) to rifampin, and (69.2%) to amoxicillin-clavulanic, that are comparable to other reports.^[@bibr27-1178633719882929],[@bibr33-1178633719882929],[@bibr34-1178633719882929]^ In the present study, high-level resistance gentamicin (HLGR) (120 μg) rate was (80%), vancomycin resistance rate was (53.8%), and teicoplanin resistance rate was (19.2%). The frequency of HLGR and glycopeptide resistance in the current study were very high compared with those of previous studies from Egypt.^[@bibr27-1178633719882929],[@bibr35-1178633719882929],[@bibr36-1178633719882929]^ Therefore, our study reveals increasing rates of resistance to gentamicin and glycopeptide, which makes the reassessment of antibiotics regimens in Egypt is very important. Erythromycin resistance in the current study was (96%), which was comparable to some reports^[@bibr37-1178633719882929]^ and higher than others.^[@bibr17-1178633719882929],[@bibr27-1178633719882929],[@bibr33-1178633719882929]^ Linezolid resistance rate in the current study was (23.1%) which was higher than that of other reports^[@bibr27-1178633719882929],[@bibr32-1178633719882929]^ while (100%) sensitivity to linezolid was reported in several studies.^[@bibr16-1178633719882929],[@bibr37-1178633719882929]^ Regarding imipenem, resistance rate was (7.6%), which was lower than other reports^[@bibr37-1178633719882929]^ and higher than others,^[@bibr38-1178633719882929]^ so, linezolid, teicoplanin, and imipenem may be the alternative treatment for hospital-acquired infections caused by *E faecalis*.

Multidrug resistance (MDR) was detected in all isolates (100%), defined by resistance to three or more Antimicrobials from different antimicrobial families^[@bibr39-1178633719882929]^ indicating a big challenge in treating infections by *E faecalis* with empirical regimens in Egypt. This MDR rate is comparable to that of previous reports.^[@bibr27-1178633719882929],[@bibr33-1178633719882929]^ High level of resistance to these antibiotics is likely related to the wide use of these antibiotics for treatment of gram-positive infections in our locality.

Macrolides are still effective for treatment of important human infections.^[@bibr40-1178633719882929]^ Cross-resistance to macrolides is caused by mutations in *erm* genes encoding methylases and/or 23 S rRNA.^[@bibr41-1178633719882929]^ Increasing rate of mutations in *erm* genes and appearance of different resistance mechanisms among the clinical pathogens show a complexity of resistance to macrolides, so studying such mechanisms between the *enterococcus* isolates is still important.^[@bibr41-1178633719882929]^ Regarding identification of erythromycin resistance mechanisms in our isolates, we found 20/26 (76.9%) of all isolates and 20/25 (80%) of erythromycin resistant isolates were positive for *ere(B)* gene, 17/26 (65.4%) of the total *E faecalis* isolates and 17/25 (68%) of erythromycin resistant isolates were positive for *erm(B)* gene. However, all (26) *E faecalis* isolates were negative for *mef(A/E)* gene. Fifteen isolates carry both *ere(B)* and *erm(B)* genes. Our findings agreed with Bello Gonzalez et al,^[@bibr42-1178633719882929]^ who reported that 8/13 (61.5) of *E faecalis* isolates carried *erm(B)* gene and no isolate was found to harbor the *mef(A/E)* gene. Reyes et al^[@bibr43-1178633719882929]^ reported that all *enterococcal* isolates with high-level resistance to erythromycin carried the *erm(B)* gene and no isolate was found to harbor the *mef(A/E)* gene. A previous study investigated *erm(B)* and *mef(A/E)* genes in *E Faecalis* isolates from urine samples in our locality reported that, 92.5% (37/40) and 2.5% (1/40) of isolates were positive for *erm(B)* and *mef(A/E)*, respectively.^[@bibr27-1178633719882929]^ Ribeiro et al^[@bibr44-1178633719882929]^ reported that 9/20 (45%) of *E Faecalis* isolates carried *ere(B)* gene^[@bibr41-1178633719882929]^; the data about *ere(B)* gene is little so our finding may give an important information about the role of *ere(B)* gene in macrolide resistance or cross-resistance not in *E faecalis* only but also in all gram-positive pathogens. *Van A* gene was detected in 71.4% of vancomycin-resistant isolates that was comparable with previous studies ^[@bibr17-1178633719882929]^ and not comparable with others.^[@bibr36-1178633719882929]^ However, some reports identified *vanA* gene in all vancomycin-resistant isolates.^[@bibr32-1178633719882929]^ *bla*TEM and blaSHV genes were not detected in our study, which agreed with some of previous studies,^[@bibr45-1178633719882929]^ and disagreed with others.^[@bibr24-1178633719882929]^

In summary, this study showed a prevalence of 8.6% *E faecalis* among 300 Egyptian patients with hospital-acquired infections. MDR in all isolates (100%) and high rates of resistance to gentamicin, erythromycin, and vancomycin were reported in *E faecalis* strain isolated from surgical wound samples and blood cultures, which considers an important health problem in the region. Erythromycin resistance in the studied isolates mainly related to the presence of *ere(B)* and *erm(B)* genes and vancomycin resistance is mainly related to *van A* gene.

In conclusion, occurrence of cross-resistance to macrolides between gram-positive pathogens due to increasing rate of mutations in resistance genes and gene transfer between different species make the studying of such mechanisms between the *enterococcus* isolates still important. Vancomycin resistance studying is also important due to increasing rates all over the world. Linezolid, teicoplanin, and imipenem represent alternative choices for Egyptian patients with hospital-acquired *E faecalis*. Screening studies like this could help in identifying effective treatment measures to control such infections.

Limitations {#section19-1178633719882929}
===========

There are two major limitations in this study that could be addressed in future research: first is that the study focused on *E faecalis* only, and second is the small sample size.
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